• The Future of Specialty Medications: What Employer Plans Need to Know

    The pipeline for specialty and advanced therapies continues to expand. Gene therapies, targeted oncology treatment, and high-cost biologics are expected to significantly affect pharmacy benefits over the next decade. Employer-sponsored health plans should start preparing now for how they are going to handle these costs. The specialty market was $92.5 billion in 2023 and could…

  • 5 Myths About Biosimilars

    Biologic drugs are medicines that come from living organisms, like genes and proteins. Biologics make up about 5% of U.S. prescriptions, but more than 50% of total prescription drug spending in the country. Biosimilar drugs are biologic drugs that are highly similar compared to their reference products, which are existing biologics. Biosimilars are not exact…

  • |

    Five Biosimilars to Watch in 2026

    The first biosimilar was approved in the U.S. in 2015. And now, just over 10 years later, the U.S. Food & Drug Administration (FDA) has approved an additional 81 biosimilars. In 2025 alone, the FDA approved 18 new biosimilars for a range of indications. However, only 73% of those approved biosimilars have been launched as of September 2025.  Last year, the  U.S. market size for biosimilars was estimated to be $22.59 billion….